Top

American Journal of Clinical Dermatology

Published in:

01-10-2018 | Short Communication

Serum Zinc Levels in Hidradenitis Suppurativa: A Case–Control Study

Authors: Inés Poveda, Eva Vilarrasa, Antonio Martorell, Francisco Javier García-Martínez, Juan Manuel Segura, Patricia Hispán, José Sánchez-Payá, Pedro José Álvarez, Iris González, José Carlos Pascual

Published in: American Journal of Clinical Dermatology | Issue 5/2018

Abstract

Background

Serum zinc levels in patients with hidradenitis suppurativa (HS) have not been previously studied.

Objective

The aim was to investigate the association between HS and serum zinc levels.

Methods

A multicenter, prospective clinical and analytical case–control study was designed to assess the possible association between HS and serum zinc levels. Consecutive patients with moderate or severe HS (Hurley II or III exclusively) were enrolled. A control population was recruited from primary care clinics. Fasting blood samples were extracted from each patient and serum zinc levels determined. Candidate predictors for low serum zinc levels were determined using logistic regression models.

Results

In total, 122 patients with HS and 122 control subjects were studied. Of the 122 HS patients, 79 (64.8%) were Hurley II and 43 (35.2%) were Hurley III. Low serum zinc levels (≤ 83.3 µg/dL) were more prevalent in HS (adjusted odds ratio [ORa] 6.7, P < 0.001). After logistic regression analysis, low serum zinc levels were associated with Hurley III (ORa 4.4, P < 0.001), Dermatology Life Quality Index ≥ 9 (ORa 3.1, P = 0.005), number of affected sites ≥ 3 (ORa 2.4, P = 0.042), genital location (ORa 2.9, P = 0.009), and perineal location (ORa 2.5, P = 0.025).

Conclusion

Low serum zinc levels are more prevalent in HS than in a healthy population, an indicator that may also be associated with disease severity.

Prens E, Deckers I. Pathophysiology of hidradenitis suppurativa: an update. J Am Acad Dermatol. 2015;73(5 Suppl 1):S8–11.CrossRefPubMed

Smith MK, Nicholson CL, Parks-Miller A, Hamzavi IH. Hidradenitis suppurativa: an update on connecting the tracts. F1000Research. 2017;6:1272.CrossRefPubMedPubMedCentral

Revuz J, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59(4):596–601.CrossRefPubMed

Jemec GB, Kimball AB. Hidradenitis suppurativa: epidemiology and scope of the problem. J Am Acad Dermatol. 2015;73(5 Suppl 1):S4–7. https://doi.org/10.1016/j.jaad.2015.07.052.CrossRefPubMed

Naldi L. Epidemiology. In: Jemec G, Revuz J, Leyden J, editors. Hidradenitis suppurativa. 1st ed. Heidelberg: Springer; 2006. p. 58–64.CrossRef

Tzellos T, Zouboulis CC, Gulliver W, Cohen AD, Wolkenstein P, Jemec GB. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2015;173(5):1142–55. https://doi.org/10.1111/bjd.14024.CrossRefPubMed

Gold DA, Reeder VJ, Mahan MG, Hamzavi IH. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2014;70(4):699–703. https://doi.org/10.1016/j.jaad.2013.11.014.CrossRefPubMed

Pascual JC, González I, Corona D, et al. Assessment of subclinical atherosclerosis in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2017;31(7):1229–38. https://doi.org/10.1111/jdv.14076.CrossRefPubMed

González-López MA, Hernández JL, Lacalle M, et al. Increased prevalence of subclinical atherosclerosis in patients with hidradenitis suppurativa (HS). J Am Acad Dermatol. 2016;75(2):329–35. https://doi.org/10.1016/j.jaad.2016.03.025.CrossRefPubMed

10.

Shavit E, Dreiher J, Freud T, Halevy S, Vinker S, Cohen AD. Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2015;29(2):371–6. https://doi.org/10.1111/jdv.12567.CrossRefPubMed

11.

Thorlacius L, Cohen AD, Gislason GH, Jemec GB, Egeberg A. Increased suicide risk in patients with hidradenitis suppurativa. J Invest Dermatol. 2018;138(1):52–7. https://doi.org/10.1016/j.jid.2017.09.008.CrossRefPubMed

12.

Kelly G, Prens EP. Inflammatory mechanisms in hidradenitis suppurativa. Dermatol Clin. 2016;34(1):51–8. https://doi.org/10.1016/j.det.2015.08.004.CrossRefPubMed

13.

Zouboulis CC, Desai N, Emtesmat L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619–44. https://doi.org/10.1111/jdv.12966.CrossRefPubMed

14.

Riis PT, Ring HC, Kjaersgaard Andersen R, Jemec GB. Self-reported minor infections in patients with hidradenitis suppurativa and healthy controls. Clin Exp Dermatol. 2018;43(2):144–8. https://doi.org/10.1111/ced.13278.CrossRefPubMed

15.

Kelly G, Sweeney CM, Tobin AM, Kirby B. Hidradenitis suppurativa: the role of immune dysregulation. Int J Dermatol. 2014;53(10):1186–96. https://doi.org/10.1111/ijd.12550.CrossRefPubMed

16.

Dréno B, Khammari A, Brocard A, et al. Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol. 2012;148(2):182–6. https://doi.org/10.1001/archdermatol.2011.315.CrossRefPubMed

17.

Ramos-Levi AM, Sánchez-Pernaute A, Rubio-Herrera MA. Dermatitis and optic neuropathy due to zinc deficiency after malabsortive bariatric surgery. Nutr Hosp. 2013;28(4):1345–7. https://doi.org/10.3305/nh.2013.28.4.6606.PubMedCrossRef

18.

Brocard A, Knol AC, Khammari A, Dréno B. Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study. Dermatology. 2007;214(4):325–7.CrossRefPubMed

19.

Brocard A, Dréno B. Innate immunity: a crucial target for zinc in the treatment of inflammatory dermatosis. J Eur Acad Dermatol Venereol. 2011;25(10):1146–52. https://doi.org/10.1111/j.1468-3083.2010.03934.x.CrossRefPubMed

20.

Bae YS, Hill ND, Bibi Y, Dreiher J, Cohen AD. Innovative uses for zinc in dermatology. Dermatol Clin. 2010;28(3):587–97. https://doi.org/10.1016/j.det.2010.03.006.CrossRefPubMed

21.

Ozuguz P, Dogruk Kacar S, Ekiz O, Takci Z, Balta I, Kalkan G. Evaluation of serum vitamins A and E and zinc levels according to the severity of acne vulgaris. Cutan Ocul Toxicol. 2014;33(2):99–102. https://doi.org/10.3109/15569527.2013.808656.CrossRefPubMed

22.

Amer M, Bahgat MR, Tosson Z, Abdel Mowla MY, Amer K. Serum zinc in acne vulgaris. Int J Dermatol. 1982;21(8):481–4.CrossRefPubMed

23.

Giacconi R, Cai L, Costarelli L, et al. Implications of impaired zinc homeostasis in diabetic cardiomyopathy and nephropathy. BioFactors. 2017;43(6):770–84. https://doi.org/10.1002/biof.1386.CrossRefPubMed

24.

Swardfager W, Herrmann N, Mazereeuw G, Goldberger K, Harimoto T, Lanctôt KL. Zinc in depression: a meta-analysis. Biol Psychiatry. 2013;74(12):872–8. https://doi.org/10.1016/j.biopsych.2013.05.008.CrossRefPubMed

25.

Gupta M, Mahajan VK, Mehta KS, Chauhan PS. Zinc therapy in dermatology: a review. Dermatol Res Pract. 2014;2014:709152. https://doi.org/10.1155/2014/709152.CrossRefPubMedPubMedCentral

26.

Hessam S, Sand M, Neier NM, Gambichler T, Scholl L, Bechara FG. Combination of oral zinc gluconate and topical triclosan: an anti-inflammatory treatment modality for initial hidradenitis suppurativa. J Dermatol Sci. 2016;84(2):197–202. https://doi.org/10.1016/j.jdermsci.2016.08.010.CrossRefPubMed

27.

Boyle M, Masson S, Anstee QM. The bidirectional impacts of alcohol consumption and the metabolic syndrome: cofactors for progressive fatty liver disease. J Hepatol. 2018;68(2):251–67. https://doi.org/10.1016/j.jhep.2017.11.006.CrossRefPubMed

28.

Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60(4):539–61. https://doi.org/10.1016/j.jaad.2008.11.911.CrossRefPubMed

29.

Wollina U, Langner D, Heinig B, Nowak A. Comorbidities, treatment, and outcome in severe anogenital inverse acne (hidradenitis suppurativa): a 15-year single center report. Int J Dermatol. 2017;56(1):109–15. https://doi.org/10.1111/ijd.13393.CrossRefPubMed

30.

Bui TL, Silva-Hirschberg C, Torres J, Armstrong AW. Hidradenitis suppurativa and diabetes mellitus: a systematic review and meta-analysis. J Am Acad Dermatol. 2018;78(2):395–402. https://doi.org/10.1016/j.jaad.2017.08.042.CrossRefPubMed

31.

Capdor J, Foster M, Petocz P, Samman S. Zinc and glycemic control: a meta-analysis of randomised placebo controlled supplementation trials in humans. J Trace Elem Med Biol. 2013;27(2):137–42. https://doi.org/10.1016/j.jtemb.2012.08.001.CrossRefPubMed

32.

Gooderham M, Papp K. The psychosocial impact of hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(5 Suppl 1):S19–22. https://doi.org/10.1016/j.jaad.2015.07.054.CrossRefPubMed

33.

Petrilli MA, Kranz TM, Kleinhaus K, et al. The emerging role for zinc in depression and psychosis. Front Pharmacol. 2017;8:414. https://doi.org/10.3389/fphar.2017.00414.CrossRefPubMedPubMedCentral

34.

Sturniolo GC, Fries W, Mazzon E, et al. Effect of zinc supplementation on intestinal permeability in experimental colitis. J Lab Clin Med. 2002;139:311–5.CrossRefPubMed

35.

Sturniolo GC, Di Leo V, Ferronato A, et al. Zinc supplementation tightens “leaky gut” in Crohn’s disease. Inflamm Bowel Dis. 2001;7:94–8.CrossRefPubMed

36.

Siva S, Rubin DT, Gulotta G. Zinc deficiency is associated with por clinical outcomes in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(1):152–7.CrossRefPubMedPubMedCentral

Title: Serum Zinc Levels in Hidradenitis Suppurativa: A Case–Control Study
Authors: Inés Poveda
Eva Vilarrasa
Antonio Martorell
Francisco Javier García-Martínez
Juan Manuel Segura
Patricia Hispán
José Sánchez-Payá
Pedro José Álvarez
Iris González
José Carlos Pascual
Publication date: 01-10-2018
Publisher: Springer International Publishing
Published in: American Journal of Clinical Dermatology / Issue 5/2018
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-018-0374-5

At a glance: The STEP trials

Springer Medicine

Serum Zinc Levels in Hidradenitis Suppurativa: A Case–Control Study

Abstract

Background

Objective

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2018

Coagulase-Negative Staphylococcus Skin and Soft Tissue Infections

Targeting the IL-23/IL-17 Pathway in Psoriasis: the Search for the Good, the Bad and the Ugly

Recent Developments in the Diagnosis and Management of Photosensitive Disorders

Diagnosis and Treatment of Vulvar Lichen Sclerosus: An Update for Dermatologists

A Comprehensive Conceptual Model of the Experience of Chronic Itch in Adults

Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma